Catherine Malaplate-Armand
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Catherine Malaplate-Armand has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
A.M. Batt
1 shared publicationC. Desbene
Laboratoire de biochimie spécialisée, hôpital Central, CHU de Nancy, CO 34, 54035 Nancy cedex, France
1 shared publication- Christine Masson
Université de Lorraine, INSERM, IGE-PCV, 54000 Nancy, France
1 shared publication Clotilde Latarche
INSERM, CIC-EC, CIE6, Université de Lorraine, Nancy, France Epidémiologie et Evaluation Cliniques, Centre Hospitalier Universitaire, Nancy, France
1 shared publication- Clotilde Latarche
INSERM, CIC-EC, CIC 1433, Nancy, France
1 shared publication - Emilie Roman
Laboratoire de biochimie et de toxicologie, secteur biochimie toxicologie, hôpital Bel Air, C.H.R Metz-Thionville, 1, rue du Friscaty, 57100 Thionville, France
1 shared publication
Latest Publications
- Open Access
- 13 May 2015
- Published by Springer Nature in BMC Neurology
- Vol. 15 (1) , 1-8
No prognostic value of routine cerebrospinal fluid biomarkers in a population-based cohort of 407 multiple sclerosis patients
We aimed to determine the association of clinical and routine cerebrospinal fluid biochemical markers (total protein, IgG index and oligoclonal bands) with disability in multiple sclerosis and whether these biomarkers assessed at diagnosis add prognostic value. We followed a cohort of patients included in the Multiple Sclerosis Lorraine Register (eastern France) who had a diagnosis of multiple sclerosis for at least 5 years, as well as biological markers values and MRI findings (Barkhof’s criteria). In a Cox regression model, endpoint was time to score of 4 on the Expanded Disability Status Scale (EDSS) (i.e., limited time walking without aid or rest for more than 500 m). For 407 patients included, the median time from multiple sclerosis onset to EDSS score 4 was 4.5 years [2.2–7.2]. Cerebrospinal fluid total protein factor < 500 mg/L was associated with EDSS score 4 on bivariate analysis (hazard ratio 0.66, 95% confidence interval 0.46–0.95, p = 0.02). On multivariate analysis, older age at disease onset (≥50 years) and initial primary progressive course of MS but not biological markers predicted worse prognosis. Routine cerebrospinal fluid biological markers at diagnosis were not prognostic factors of multiple sclerosis progression.
- 13 May 2015
- Published by Springer Nature in BMC Neurology
- Vol. 15 (1) , 1-8
Open AccessNo prognostic value of routine cerebrospinal fluid biomarkers in a population-based cohort of 407 multiple sclerosis patients
We aimed to determine the association of clinical and routine cerebrospinal fluid biochemical markers (total protein, IgG index and oligoclonal bands) with disability in multiple sclerosis and whether these biomarkers assessed at diagnosis add prognostic value. We followed a cohort of patients included in the Multiple Sclerosis Lorraine Register (eastern France) who had a diagnosis of multiple sclerosis for at least 5 years, as well as biological markers values and MRI findings (Barkhof’s criteria). In a Cox regression model, endpoint was time to score of 4 on the Expanded Disability Status Scale (EDSS) (i.e., limited time walking without aid or rest for more than 500 m). For 407 patients included, the median time from multiple sclerosis onset to EDSS score 4 was 4.5 years [2.2–7.2]. Cerebrospinal fluid total protein factor < 500 mg/L was associated with EDSS score 4 on bivariate analysis (hazard ratio 0.66, 95% confidence interval 0.46–0.95, p = 0.02). On multivariate analysis, older age at disease onset (≥50 years) and initial primary progressive course of MS but not biological markers predicted worse prognosis. Routine cerebrospinal fluid biological markers at diagnosis were not prognostic factors of multiple sclerosis progression.
- 23 June 2014
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 41 (2) , 377-386
Additional Use of Aβ42/Aβ40 Ratio with Cerebrospinal Fluid Biomarkers P-Tau and Aβ42 Increases the Level of Evidence of Alzheimer's Disease Pathophysiological Process in Routine Practice
Background: Cerebrospinal fluid (CSF) biomarkers have recently been included in the criteria for the diagnosis of Alzheimer’s disease (AD). Since interpretation of CSF profile requires the combination of three parameters, biological data are not alwa
- 23 June 2014
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 41 (2) , 377-386
Additional Use of Aβ42/Aβ40 Ratio with Cerebrospinal Fluid Biomarkers P-Tau and Aβ42 Increases the Level of Evidence of Alzheimer's Disease Pathophysiological Process in Routine Practice
Background: Cerebrospinal fluid (CSF) biomarkers have recently been included in the criteria for the diagnosis of Alzheimer’s disease (AD). Since interpretation of CSF profile requires the combination of three parameters, biological data are not alwa
- 31 July 2009
- Published by Elsevier in Revue Neurologique
- Vol. 165 (6-7) , 511-520
Diagnostic biologique de la maladie d’Alzheimer : avancées, limites et perspectives
- 31 July 2009
- Published by Elsevier in Revue Neurologique
- Vol. 165 (6-7) , 511-520
Diagnostic biologique de la maladie d’Alzheimer : avancées, limites et perspectives
- 1 December 2005
- Published by Elsevier in Toxicology Letters
- Vol. 159 (3) , 203-211
Down-regulation of astroglial CYP2C, glucocorticoid receptor and constitutive androstane receptor genes in response to cocaine in human U373 MG astrocytoma cells
- 1 December 2005
- Published by Elsevier in Toxicology Letters
- Vol. 159 (3) , 203-211
Down-regulation of astroglial CYP2C, glucocorticoid receptor and constitutive androstane receptor genes in response to cocaine in human U373 MG astrocytoma cells